Revenue Performance - The total revenue for the six months ended June 30, 2023, decreased to RMB 350 million from RMB 572 million for the same period in 2022, representing a decline of approximately 38.8%[7] - The company's revenue for the reporting period was approximately RMB 35.0 million, a decrease of about 38.8% compared to the same period in 2022[21] - The company reported revenue of RMB 34,985,000 for the six months ended June 30, 2023, a decrease of 38.5% compared to RMB 57,190,000 for the same period in 2022[100] - Customer contract revenue for the six months ended June 30, 2023, was RMB 34,985,000, a decrease of 38.8% compared to RMB 57,190,000 for the same period in 2022[124] Patient Activity - The total number of active patients across the five private dental hospitals decreased from 39,680 to 30,366, a reduction of about 23.5%[13] - The number of active patients at Wenzhou Hospital dropped from 23,811 to 18,908, reflecting a decrease of about 20.5%[13] - The average number of visits for dental services decreased from 29,700 to 23,700, leading to a revenue drop in the oral comprehensive treatment department by approximately 8.5%[22] - Revenue from the orthodontics department decreased by approximately 30.7%, with visits dropping from 5,200 to 3,500[23] - The company noted a gradual increase in patient visits as the impact of COVID-19 diminishes[7] - The company’s subsidiary, Wenzhou Dental Hospital, has reported a 25% increase in patient visits, contributing significantly to overall revenue growth[146] Hospital Revenue Contributions - Revenue contributions from the Wenzhou Hospital accounted for approximately 65.1% of total revenue for the six months ended June 30, 2023, generating RMB 22.76 million[14] - The revenue from the Lucheng Hospital decreased from RMB 13.04 million to RMB 5.05 million, a decline of approximately 61.1%[14] - The revenue from the Wenzhou Oral Hospital decreased from RMB 7.53 million to RMB 3.67 million, a decline of approximately 51.2%[14] - The total revenue from the Longgang Hospital was RMB 2.11 million, contributing 6.0% to total revenue, down from 4.8% in the previous year[14] Financial Performance - Gross profit decreased by approximately 52.6% to about RMB 15.5 million, with the gross margin dropping to approximately 44.2%[28] - The group recorded a loss attributable to the owners of the company of approximately RMB 2.1 million during the reporting period, compared to a profit of RMB 10.9 million for the six months ended June 30, 2022[33] - The company incurred a loss before tax of RMB 2,751,000, compared to a profit of RMB 15,423,000 in the prior year[100] - The net loss attributable to equity holders of the parent was RMB 2,122,000, a significant decline from a profit of RMB 10,863,000 in the same period last year[100] - The company reported a total comprehensive income of RMB 1,005,000 for the six months ended June 30, 2023, compared to RMB 10,873,000 in the previous year[102] Expenses and Cost Management - Selling expenses rose by approximately 63.3% to RMB 9.8 million, attributed to an increase in sales and marketing personnel[30] - Administrative expenses decreased by approximately 9.0% to RMB 10.1 million, influenced by the absence of listing expenses incurred in the previous year[31] - Employee benefit expenses for the reporting period amounted to approximately RMB 20.2 million, an increase of approximately RMB 1.2 million compared to RMB 19.0 million in the same period of 2022[41] - The cost of inventory, consumables, and customized products for the six months ended June 30, 2023, was RMB 5,066,000, down from RMB 6,892,000 in 2022, indicating a reduction of 26.5%[126] Future Outlook and Expansion Plans - The company expressed confidence in future growth due to the gradual recovery from COVID-19 and government support policies[7] - The company plans to expand its dental services in Wenzhou and establish new private dental hospitals to capture rising demand[17] - The company aims to enhance its operational efficiency by upgrading its business operation software systems across its dental hospitals[18] - The company plans to allocate approximately 28.6% of its net proceeds (RMB 21.5 million) for potential strategic acquisitions of two dental hospitals in China by June 2024[95] - The company is planning to expand its market presence by opening two new clinics in Zhejiang province by the end of 2023[146] Capital and Assets - As of June 30, 2023, the group's current assets net value was approximately RMB 135.4 million, with a current ratio of 4.5 times[36] - The group had no bank loans as of June 30, 2023, maintaining a debt-free status[36] - The group had a bank balance of approximately RMB 147.5 million as of June 30, 2023, up from RMB 89.5 million as of December 31, 2022[36] - Total assets less current liabilities as of June 30, 2023, amounted to RMB 208,434,000, a decrease of 1.3% from RMB 211,490,000 as of December 31, 2022[107] - Non-current assets totaled RMB 73,071,000 as of June 30, 2023, down from RMB 76,211,000 at the end of 2022, reflecting a decline of 4.1%[105] Shareholder and Corporate Governance - As of June 30, 2023, the company had a total of 600,000,000 shares issued, with major shareholders JTC BVI and Ricon BVI holding 337,500,000 shares (56.25%) and 45,000,000 shares (7.5%) respectively[56] - The company adopted a share option scheme on November 8, 2022, with a maximum issuance limit of 60,000,000 shares, equivalent to 10% of the total shares issued as of the report date[61] - The company’s directors and senior management hold a combined interest of 71.25% in the company through controlled corporations[55] - The group did not recommend the payment of an interim dividend for the six months ended June 30, 2023, consistent with the previous year[129] Regulatory and Compliance Issues - The company faces risks related to the contractual arrangements, including potential regulatory changes and conflicts of interest with shareholders of the variable interest entity[87] - The company must adhere to specific regulations regarding foreign investment in medical institutions, with local partners required to hold at least 30% equity[85] - The company has received exemptions from the Stock Exchange regarding certain ongoing connected transactions under the contractual arrangements[89] - The group confirmed no significant changes in contractual arrangements with variable interest entities in the six months ending June 30, 2023[81]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 截至二零二三年六月三十日止六個月的中期業績公告 財務摘要 截至六月三十日止六個月 二零二三年 二零二二年 六月三十日 六月三十日 （人民幣千元）（人民幣千元） （未經審核） （未經審核） 收益 34,985 57,190 銷售成本 (19,517) (24,456) 毛利 15,468 32,734 除稅前（虧損）╱溢利 (2,751) 15,423 期間（虧損）╱溢利 (2,120) 10,873 期間經調整（虧損）╱溢利 (2,120) 14,408 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 茲提述美皓醫療集團有限公司（「本公司」）日期為二零二三年三月二十九日的公告（「該公 告」），內容有關本公司及其附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年 度的經審核綜合財務業績，及本公司截至二零二二年十二月三十一日止年度的年度報告 （「年報」）。除另有界定者外，本公告所用詞彙與該公告及年報所界定者具有相同涵義。 除該公告及年報所披露的資料外，本公司謹此向其股東及本公司潛在投資者就年報第12頁 所披露本公司於二零二二年十二月三十一日的預付款項、其他應收款項及其他資產提供以 下補充資料： 應收包銷商首次公開發售款項（「應收首次公開發售款項」）約人民幣67.1百萬元包含在本公 司 ...

Financial Performance - The company reported a revenue increase from RMB 1.053 billion to RMB 1.274 billion, representing a growth of approximately 21.0%[10]. - The company recorded revenue of approximately RMB 127.4 million for the year ended December 31, 2022, an increase from RMB 105.3 million in 2021, representing a growth of about 21.0%[20]. - The net profit for the year ended December 31, 2022, was approximately RMB 28.6 million, a decrease of about 11.2% compared to RMB 32.2 million in 2021, primarily due to increased listing expenses[20]. - The group's gross profit increased by approximately 16.9% to RMB 78.2 million, with a slight decrease in gross margin to about 61.4%[41]. - Other income and gains rose by approximately 482.4% to RMB 9.9 million, primarily due to increased government subsidies related to the listing[42]. - Selling expenses increased by approximately 256.9% to RMB 18.2 million, mainly due to heightened marketing and promotional expenditures[43]. - Administrative expenses rose to approximately RMB 27.0 million, an increase of about RMB 9.5 million, largely due to increased listing expenses[44]. Patient and Service Growth - The number of active patients at dental hospitals increased from 61,910 to 63,659 during the year[10]. - The total number of active patients increased from 61,910 in 2021 to 63,659 in 2022, reflecting a growth of 2.83%[26]. - The Wenzhou Hospital contributed approximately 60.1% of total revenue in 2022, generating RMB 76.5 million, compared to 70.2% in 2021[27][28]. - The company plans to expand its dental services in Wenzhou by establishing new private dental hospitals to capture rising demand and enhance market presence[30]. - The company aims to penetrate the pediatric dental market, believing that demand from child patients will be a major growth driver in the dental services market[30]. Financial Position and Assets - Cash and cash equivalents rose by approximately 116.7%, reaching RMB 895 million by the end of 2022[10]. - The company's net asset value significantly increased from RMB 505 million in 2021 to RMB 1.778 billion in 2022[10]. - As of December 31, 2022, the group's current assets net amount was approximately RMB 135.3 million, with a current ratio of 4.3 times[48]. - The group had a capital commitment of approximately RMB 2.1 million for leasing property renovations and medical equipment as of December 31, 2022, compared to RMB 0.5 million in 2021[51]. Management and Governance - The management team includes co-founders with nearly 18 years of experience in the dental service industry[59][63]. - The management team includes professionals with extensive backgrounds in finance, healthcare, and technology, ensuring a diverse skill set[70][71]. - The board consists of five members, including two executive directors and three independent non-executive directors, ensuring a balanced mix of skills and experiences[105]. - The company has adopted a board diversity policy that includes criteria such as gender, age, cultural background, and professional qualifications[105]. - The company provides ongoing professional development for directors to keep them updated on regulatory changes and responsibilities[101]. Risk Management and Compliance - The company has implemented multiple systems to identify potential risks related to its business, including quality control systems and emergency response protocols[131]. - The board acknowledges its responsibility for the effectiveness of the risk management and internal control systems[133]. - The company has a zero-tolerance policy towards bribery and corruption, with established reporting mechanisms for corruption allegations[134]. - The audit committee is responsible for overseeing the internal control procedures and ensuring compliance with regulatory requirements[131]. - The company has not established an internal audit function, considering the scale and complexity of its operations[131]. Market and Economic Environment - The overall economic environment in China showed challenges, with GDP growth at only 1% in the second quarter of 2022[9]. - The average disposable income of Wenzhou residents grew by 5.8% year-on-year, reaching RMB 63,033[9]. - The company anticipates a recovery in consumer and retail markets in 2023 as COVID-19 restrictions ease, presenting opportunities for growth[29]. Strategic Plans and Future Outlook - The company aims to strengthen its market position in China following its successful listing on the Hong Kong Stock Exchange on December 14, 2022[8]. - The company plans to implement prudent financial management and cost control to explore suitable business opportunities for growth[10]. - The company is exploring expansion plans into new regions, which carry uncertainties and risks[165]. - New dental clinics will be established outside Wenzhou under a new brand name[91]. - The company will purchase new dental equipment and supplies to enhance service quality[91]. Shareholder Relations and Communication - The company acknowledges the importance of effective communication with shareholders to enhance investor relations and understanding of its business and strategies[147]. - The board of directors is committed to ensuring that all resolutions presented at the annual general meeting are voted on according to listing rules, with results published post-meeting[148]. Contractual Arrangements and Legal Compliance - The exclusive purchase agreement was established on January 16, 2020, and August 26, 2021, ensuring compliance with legal regulations and protecting asset value[184]. - The shareholders' rights entrustment agreement grants 德鴻醫療 control over 100% of 天睿醫療 and other subsidiaries, ensuring decision-making authority[188]. - The company has not faced any intervention or obstruction from Chinese regulatory authorities regarding its contractual arrangements as of December 31, 2022[195]. - The contractual arrangements are specifically designed to address foreign ownership restrictions and align with the company's business objectives while minimizing legal conflicts in China[197].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Meihao Medical Group Co., Ltd 美 皓 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1947） 截至二零二二年十二月三十一日止年度的年度業績公告 財務摘要 . 收益增加約21.0%至約人民幣127.4百萬元（二零二一財年：約人民幣105.3百萬元） . 除稅前溢利減少約8.0%至約人民幣40.2百萬元（二零二一財年：約人民幣43.7百萬元） . 本公司權益持有人應佔溢利減少約11.2%至約人民幣28.5百萬元（二零二一財年：約 人民幣32.1百萬元） . 經調整溢利淨額（不包括上市開支）增加約10.8%至約人民幣38.1百萬元（二零二一財 年：約人民幣34.4百萬元） . 母公司普通權益持有人應佔每股盈利減少約12.8%至約人民幣6.22分（二零二一財 年：約人民幣7.13分） ...